Back to Search Start Over

Terran Biosciences Receives FDA Clearance for NM-101, the industry's first software for the analysis of neuromelanin-sensitive MRI

Source :
Business Wire. December 20, 2023
Publication Year :
2023

Abstract

MIAMI -- Terran Biosciences, Inc. ('Terran'), a biotech platform company developing therapeutics and technologies for patients with neuropsychiatric illnesses, has received FDA clearance to market NM-101, a cloud-based software platform [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
Business Wire
Publication Type :
News
Accession number :
edsgcl.776814974